Immix Biopharma Inc Stock Price, News & Analysis

Immix Biopharma (IMMX) has announced a conference call scheduled for Tuesday, December 10, 2024, at 4:30 p.m. Eastern Time. The call will feature company management providing updates on positive new developments regarding CAR-T NXC-201 in relapsed/refractory AL Amyloidosis.

The clinical-stage biopharmaceutical company, which focuses on developing cell therapies for AL Amyloidosis and select immune-mediated diseases, will host the call via Zoom. Following management's formal presentation, attendees will have the opportunity to participate in a question-and-answer session.

Immix Biopharma (IMMX) announced positive clinical data for NXC-201 in treating relapsed/refractory AL Amyloidosis patients, achieving a 75% complete response rate (12/16 patients) with median 4 prior lines of therapy. The data will be presented at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego on December 9, 2024. NXC-201 is highlighted as the only CAR-T therapy in development for this condition, demonstrating promising results in this underserved patient population.

Immix Biopharma (IMMX) has advanced its CAR-T therapy NXC-201 to the expansion cohort dose level in the U.S. NEXICART-2 trial for AL Amyloidosis. The study is now dosing at 450 million NXC-201 CAR+T cells, following successful completion of the first cohort at 150 million cells. Both doses have previously produced complete responses in clinical studies.

NXC-201 is the only one-time CAR-T treatment being studied for relapsed/refractory AL Amyloidosis in U.S. clinical trials. The NEXICART-2 study, led by Memorial Sloan Kettering Cancer Center, aims to evaluate the safety and efficacy of NXC-201 in patients with adequate cardiac function who haven't received prior BCMA-targeted therapy.

Previous data from an ex-US study showed a 92% overall response rate and a 28.0 month duration of response. AL Amyloidosis, affecting approximately 33,000 patients in the U.S., currently has no FDA-approved drugs for relapsed/refractory cases.

Immix Biopharma (IMMX) has announced that Dr. Raymond Comenzo, an internationally recognized AL Amyloidosis expert, has joined the Scientific Advisory Board of its subsidiary Nexcella. Dr. Comenzo, Director of the Myeloma and Amyloid Program at Tufts Medical Center, is renowned for his pioneering work in developing consensus guidelines for clinical trials and response criteria in AL Amyloidosis. He was the senior author of the landmark Andromeda trial results, which led to the first FDA-approved therapy for AL amyloidosis.

Dr. Comenzo expressed excitement about joining Nexcella's efforts to advance CAR-T NXC-201 for treating relapsed/refractory AL Amyloidosis, an area with no currently approved drugs. Immix Biopharma's leadership believes Dr. Comenzo's expertise will greatly benefit their research and development efforts in this field.

Immix Biopharma (NASDAQ: IMMX) has expanded its U.S. clinical trial sites for the NEXICART-2 study, evaluating CAR-T NXC-201 in relapsed/refractory AL Amyloidosis patients. New sites include Cleveland Clinic, UC Davis, and Sutter Health, joining lead site Memorial Sloan Kettering Cancer Center. This expansion aims to increase patient access and enrollment opportunities across the U.S.

The study builds on positive data from the ex-U.S. NEXICART-1 trial, which showed a 92% overall response rate in relapsed/refractory AL Amyloidosis patients. NXC-201 is currently the only CAR-T therapy in development for AL Amyloidosis. The expansion supports upcoming interim and final read-outs of NEXICART-2, as Immix Biopharma continues its mission to advance treatment options for this patient population.

Immix Biopharma (Nasdaq: IMMX) has been awarded an $8 million CLIN2 grant from the California Institute for Regenerative Medicine (CIRM) to support the clinical development of NXC-201, a CAR-T cell therapy for relapsed/refractory AL Amyloidosis. The funding will be used for the NEXICART-2 U.S. clinical trial, which aims to evaluate the safety and efficacy of NXC-201 in patients with adequate cardiac function who have not received prior BCMA-targeted therapy.

The decision follows promising results from the ex-U.S. NEXICART-1 study, which showed a 92% overall response rate in relapsed/refractory AL Amyloidosis patients. NXC-201 is currently the only CAR-T therapy in development for AL Amyloidosis, a rare disease with treatment options. The therapy's potential has been recognized in a recent New England Journal of Medicine review article.

Immix Biopharma has dosed the first patient in its U.S. NEXICART-2 trial for AL Amyloidosis at Memorial Sloan Kettering Cancer Center. The trial aims to assess the safety and efficacy of NXC-201, a BCMA-targeted CAR-T cell therapy, in patients with relapsed or refractory AL Amyloidosis. This follows positive results from the ex-U.S. NEXICART-1 trial, which showed a 92% overall response rate. The trial's initiation is in line with Immix Biopharma's mid-2024 guidance. NXC-201 could become a first-in-class treatment for AL Amyloidosis, with no approved drugs currently available for relapsed cases.

Immix Biopharma, a clinical-stage biopharmaceutical company, announced their participation in the Stifel 2024 Cell Therapy Forum on July 9, 2024. The event will be held virtually, where Immix Biopharma will present and host institutional investor meetings. The company specializes in developing cell therapies for autoimmune diseases and aims to engage with institutional investors during this forum to discuss their advancements and business strategies.

Immix Biopharma, Inc. announced positive clinical data for NXC-201 in treating relapsed/refractory AL Amyloidosis patients, showcasing a 92% overall response rate with 75% complete responders. The impressive response rates and durability of the treatment highlight its potential as a new option for patients. The company plans to proceed with the NEXICART-2 clinical trial in mid-2024 based on the positive outcomes of the NEXICART-1 study.